PTEN loss in thyroid cancer can lead to resistance to BRAF inhibitors due to the interconnected nature of the PI3K/AKT pathway, which is regulated by PTEN, and the MAPK pathway, which is driven by mutant BRAF. The gene discussed is PTEN; the disease is thyroid gland carcinoma.